Skip to main content

Hot Corner Insider Buys

Displaying 217 - 228 of 314

Hot Corner Insider

Buffett Reports an $85 Million Buy

January 17, 2024

From the Desk of Steve Strazza and Alfonso Depablos

The largest insider buy on today’s list comes via Form 4 filings by Warren Buffett and Berkshire Hathaway.

Buffett and Berkshire reported purchases in The Liberty SiriusXM Group  for a total amount of $84,970,847.

Hot Corner Insider

CEO Frost Buys 1,000,000 OPK Shares

January 16, 2024

From the Desk of Steve Strazza and Alfonso Depablos

The largest insider buy on today’s list comes via a handful of filings by the CEO and chairman of OPKO Health $OPK, Phillip Frost.

Frost reported a total purchase of 1,000,000 OPK shares, equivalent to $954,300.

Hot Corner Insider

Insiders Are Buying TLRY Shares

January 16, 2024

From the Desk of Steve Strazza and Alfonso Depablos

The largest insider buy on today’s list comes in the form of filings by the CEO, the CFO, and the global general counsel of Tilray Brands Inc $TLRY.

Each filed Form 4s revealing combined purchases of TLRY shares in the total amount of $148,454.

Hot Corner Insider

Baker Bros Boosts Its KYMR, REPL Stakes

January 10, 2024

From the Desk of Steve Strazza and Alfonso Depablos

The largest insider buy on today’s list comes in a 13G filing by Baker Bros Advisors LP.

The hedge fund increased its ownership position in Kymera Therapeutics Inc $KYMR from 9.2% to 10.8%.

Hot Corner Insider

CEO Wentworth Buys 10,000 WBA Shares

January 8, 2024

From the Desk of Steve Strazza and Alfonso Depablos

The largest insider buy on today’s list comes in a Form 4 filing by Timothy C. Wentworth, CEO of Walgreens Boots Alliance $WBA..

Wentworth reported a purchase of 10,000 WBA shares, equivalent to $242,220.

Hot Corner Insider

Point72 Takes a 5.4% Stake in CCCC

January 4, 2024

From the Desk of Steve Strazza and Alfonso Depablos

The only transaction on today’s list comes in a 13G filed  by Point72 Asset Management.

The hedge fund revealed an initial stake of 5.40% in C4 Therapeutics Inc $CCCC.